COLLABORATION
Strategic Collaborations and Business Model
- CalAsia has developed a flexible business model to create shareholder value to its investors and partners:
- CalAsia has its own internal pipeline of new chemical entities using the power of differential fragment screening (DFS) on promising drug targets
- CalAsia is collaborating with research institutions to broaden its intellectual property and strengthen its internal pipeline, including the Sanford-Burnham Institute for Medical Research, La Jolla CA; Cleveland State University, Cleveland, OH; John Hopkins University, Baltimore, MD; Boston College Boston, MA; and Georgetown University Washington, DC.
- Pharmaceutical and Biotech companies can access into CalAsia's extensive expertise and portfolio of drug targets to advance their internal drug discovery program from the current list shown in the table below
Collaborators
Structure Based Drug Discovery Targets for Partnering and Collaboration
CalAsia Pharmaceuticals Business Model
